Early outcomes with a fully retrievable SinoCrown transcatheter heart valve in patients with severe aortic stenosis

IF 2.1 3区医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Catheterization and Cardiovascular Interventions Pub Date : 2024-09-26 DOI:10.1002/ccd.31230

Yuehuan Li MD, Zhongyu Xiong MN, Ruobing Lei PhD, Jiangang Wang MD, Haibo Zhang MD

{"title":"Early outcomes with a fully retrievable SinoCrown transcatheter heart valve in patients with severe aortic stenosis","authors":"Yuehuan Li MD, Zhongyu Xiong MN, Ruobing Lei PhD, Jiangang Wang MD, Haibo Zhang MD","doi":"10.1002/ccd.31230","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>This study summarizes and analyzes data from patients suffering from symptomatic aortic stenosis who successfully underwent transcatheter aortic valve implantation (TAVI) using a novel, completely retrievable transcatheter heart valve.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We included patients who underwent a TAVI procedure with SinoCrown valves at our center between December 2021 and September 2022. We collected 1-year follow-up data on survival, complications, echocardiographic results, New York Heart Association functional class in heart failure, and patient-reported health-related quality of life outcomes.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Eight successive patients (73.3 ± 4.3 years) were included in the study, with a median Society of Thoracic Surgery risk score of 4.26%. The procedure had a 100% success rate. Median postoperative discharge time was 7 days, with no 30-day hospital readmissions. Postoperative aortic valve hemodynamics improved, indicated by decreased transvalvular flow velocity compared with preoperative values (1.9 ± 0.2 vs. 4.9 ± 0.2 m/s, <i>p</i> < 0.0001). The median and maximum follow-up times were 8 and 12 months, respectively. During the follow-up period, there were no serious complications such as death, stroke, valve embolization, or high-grade atrioventricular block.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>The results from eight initial TAVI cases performed with the SinoCrown valve demonstrated promising safety and efficacy.</p>\n </section>\n </div>","PeriodicalId":9650,"journal":{"name":"Catheterization and Cardiovascular Interventions","volume":"104 6","pages":"1267-1274"},"PeriodicalIF":2.1000,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Catheterization and Cardiovascular Interventions","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/ccd.31230","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Background

This study summarizes and analyzes data from patients suffering from symptomatic aortic stenosis who successfully underwent transcatheter aortic valve implantation (TAVI) using a novel, completely retrievable transcatheter heart valve.

Methods

We included patients who underwent a TAVI procedure with SinoCrown valves at our center between December 2021 and September 2022. We collected 1-year follow-up data on survival, complications, echocardiographic results, New York Heart Association functional class in heart failure, and patient-reported health-related quality of life outcomes.

Results

Eight successive patients (73.3 ± 4.3 years) were included in the study, with a median Society of Thoracic Surgery risk score of 4.26%. The procedure had a 100% success rate. Median postoperative discharge time was 7 days, with no 30-day hospital readmissions. Postoperative aortic valve hemodynamics improved, indicated by decreased transvalvular flow velocity compared with preoperative values (1.9 ± 0.2 vs. 4.9 ± 0.2 m/s, p < 0.0001). The median and maximum follow-up times were 8 and 12 months, respectively. During the follow-up period, there were no serious complications such as death, stroke, valve embolization, or high-grade atrioventricular block.

Conclusions

The results from eight initial TAVI cases performed with the SinoCrown valve demonstrated promising safety and efficacy.

查看原文本刊更多论文

重度主动脉瓣狭窄患者使用完全可回收的 SinoCrown 经导管心脏瓣膜的早期疗效。

背景：本研究总结并分析了使用新型、完全可回收的经导管心脏瓣膜成功进行经导管主动脉瓣植入术（TAVI）的无症状主动脉瓣狭窄患者的数据：我们纳入了2021年12月至2022年9月期间在本中心接受SinoCrown瓣膜TAVI手术的患者。我们收集了1年的随访数据，包括生存率、并发症、超声心动图结果、纽约心脏协会心衰功能分级以及患者报告的健康相关生活质量结果：连续八名患者（73.3 ± 4.3 岁）被纳入研究，胸外科学会风险评分中位数为 4.26%。手术成功率为 100%。术后出院时间中位数为 7 天，无 30 天再住院病例。术后主动脉瓣血流动力学有所改善，经瓣血流速度与术前值相比有所下降（1.9 ± 0.2 vs. 4.9 ± 0.2 m/s，p）：使用SinoCrown瓣膜进行的8例初次TAVI手术结果表明，SinoCrown瓣膜具有良好的安全性和有效性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Catheterization and Cardiovascular Interventions 医学-心血管系统

CiteScore

5.40

自引率

8.70%

发文量

419

审稿时长

2 months

期刊介绍： Catheterization and Cardiovascular Interventions is an international journal covering the broad field of cardiovascular diseases. Subject material includes basic and clinical information that is derived from or related to invasive and interventional coronary or peripheral vascular techniques. The journal focuses on material that will be of immediate practical value to physicians providing patient care in the clinical laboratory setting. To accomplish this, the journal publishes Preliminary Reports and Work In Progress articles that complement the traditional Original Studies, Case Reports, and Comprehensive Reviews. Perspective and insight concerning controversial subjects and evolving technologies are provided regularly through Editorial Commentaries furnished by members of the Editorial Board and other experts. Articles are subject to double-blind peer review and complete editorial evaluation prior to any decision regarding acceptability.